DN Capital, Early Backer of Auto1, Shazam and OLX, Launches New $350m Fund to Shape Post-pandemic World
DN Capital, one of Europe’s most established Venture Capital firms, today announces the launch of its latest $350m (£220m, €300m) fund. In a year which has already seen four of the DN Capital portfolio reach billion dollar-plus valuations, the firm’s Fund V will back the most ambitious early stage entrepreneurs across Europe, the UK and the US, who are creating businesses built on the pandemic-accelerated surge in digital adoption, and developing technologies critical to the global recovery.
Under the leadership of private equity and VC stalwarts Nenad Marovac and Steve Schlenker - who head up a senior team with a combined 100 years-plus of investment experience - DN’s predominantly young and ambitious team has a consistent track record of partnering with some of Europe’s most promising startups, long before they became market leaders.
‘Think Big and Global”
Known for their ‘Think Big and Global’ approach to startup investing, the firm was one of Shazam’s earliest backers in 2004, and helped guide the London-born app through to Apple’s acquisition in 2018. DN Capital led the Series A round in Auto1, which floated on the German Stock Exchange earlier this year at a valuation over $10 billion and over 150x their entry price per share. Just recently in July 2021 the online eyewear retailer MrSpex also saw a strong IPO debut, valuing the company at over $1.0bn. DN Capital’s first billion dollar exit was Endeca which was sold to Oracle for $1.1bn in 2011. In its current portfolio US remittance business Remitly, digital staffing company Jobandtalent and the online education company GoStudent are amongst the latest unicorns and have recently closed billion-dollar financing rounds.
Fund V, which was substantially oversubscribed, will double-down on DN Capital’s strategy of finding and supporting the next generation of global category leaders specifically in its core fields of software, fintech, marketplaces and the consumer internet. Roughly two thirds of the firm’s investments have been made in Europe, through its London and Berlin hubs, with the remainder originating in its Silicon Valley office in Menlo Park.
For the journey
With a proven ability to identify founders with unicorn potential at the earliest stages, a worldwide advisor network, a deep 20-year track record, and a reputation for insightful business model understanding, DN Capital has established itself as a persistent outlier in European and US venture capital. It has proven to give founders the best possible platform for their scale-up journey, while being able to introduce its portfolio teams to top tier growth-stage investors.
“We’ve always preferred to let our founders and their incredible numbers talk for us,” says Nenad Marovac DN Capital’s founder. “When we say we only partner with the best, we mean it. We spend vast amounts of time with entrepreneurs understanding the market, their team, their product and to get to the heart of what they’re trying to achieve, long before we even talk about money. Then we work together with the entrepreneurs as partners to help them where they need it.
“The launch of our fifth fund gives us further scope to uncover new entrepreneurs with the biggest, brightest global ambitions. We pride ourselves on the fact that we work as hard as founders do to help them build their businesses, and this is something that’s going to be even more crucial as we, as a society, look to come back stronger following the pandemic,” he says.
DN Capital co-founder and managing partner Steve Schlenker believes the full impact of the pandemic on society, work, and behaviours is only just being understood, and that—when it happens--the recovery around the world will be powered by innovation and technology. “There are tech founders across the globe right now on critical missions to accelerate this recovery and help address the needs, and solve the biggest problems, of the post-COVID world,” he says. “At DN Capital we are committed to supporting them to achieve these goals.”
Partner Thomas Rubens adds: “We have backed numerous category defining businesses and we know what it takes to scale global companies. We have the youth and ambition in our team, as well as the huge global network, to be right at the cutting-edge of the next important trends. Especially those trends born out of the drastic, era-defining change we are witnessing today.”
“From the very start of our journey, Nenad, who was on our Board throughout, and the wider DN Capital team, supported us not just with strategic advice but helped us launch in the US, hire senior executives—including myself—and also introduced Apple,” says Andrew Fisher, Shazam’s former CEO and executive chairman. “The founder-investor relationship can be make-or-break for early stage entrepreneurs.”
Hakan Koc, co-founder and CEO at Auto1, said: ““ Since DN led the Series A in Auto1 we always enjoyed working with Nenad, Steve and the team. From the outset they saw the potential in us and Auto1 Group and understood how best to support us.”
Felix Ohswald, co-founder and CEO of GoStudent, said: “Expanding into 18 markets in just over two years is never easy but with DN Capital on our side we knew we could do it and in forging the connection with our next investors - DST, Softbank and Tencent - they helped us to take that next big leap.”
To view this piece of content from cts.businesswire.com, please give your consent at the top of this page.
+44 7909 985 621
About Business Wire
Subscribe to releases from Business Wire
Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.
Latest releases from Business Wire
Relief Announces Receipt of U.S. FDA Orphan Drug Designation for the use of RLF-100 (aviptadil) in the Treatment of Sarcoidosis3.8.2021 07:03:00 CEST | Press release
RELIEF THERAPEUTICS Holding AG (SIX: RLF, OTCQB: RLFTF) (“Relief” or the "Company"), a biopharmaceutical company seeking to provide patients therapeutic relief from serious diseases with high unmet need, reported today that, via its newly acquired subsidiary, AdVita Lifescience GmbH, the Company has been granted Orphan Drug Designation by the U.S. Food and Drug Administration (“FDA”) for RLF-100 (aviptadil), an inhaled formulation in development for the treatment of sarcoidosis. RLF-100 is a synthetic form of vasoactive intestinal peptide. In open label exploratory clinical experience in sarcoidosis patients, RLF-100 has been shown to be well tolerated and safe, and to produce favorable immunoregulatory effects in the lungs that have been associated with symptom relief in a significant proportion of the patients. “Receipt of our third Orphan Drug Designation is another important milestone for the Company, as it underscores the potential strength of our pipeline and the high need for be
Smart Engages P.I. Works for Expanded Network Automation Solution3.8.2021 07:00:00 CEST | Press release
Smart Communications, Inc. (Smart), the wireless unit of the Philippines’ largest, fully integrated telecommunications company PLDT, has partnered with P.I. Works for a comprehensive strategy for its Self-Organizing Network (SON) Solution to automate its multi-vendor, multi-technology networks. A self-organizing network (SON) is an automation technology designed to make the planning, configuration, performance management, coverage and quality optimization and healing of mobile radio access networks efficient, simpler and faster. This automation is expected to significantly improve the performancemanagement and service quality enhancements of the Smart wireless network, which will result in an improved experience for Smart customers across the country. Under its Network Operations Transformation program, Smart started working with P.I. Works in 2018 through another entity, to enable Artificial Intelligence (AI) and Machine Learning (ML) technologies for the automation of various network
Personalis, Inc. Publishes New Data Demonstrating a Novel Composite Biomarker NEOPS™ for Predicting Response to Cancer Immunotherapy in Late-Stage Melanoma Patients2.8.2021 22:05:00 CEST | Press release
Personalis, Inc. (Nasdaq: PSNL), a leader in advanced translational genomics and diagnostics for cancer, today announced the publication of its study "Prediction of immunotherapy response in melanoma through combined modeling of neoantigen burden and immune-related resistance mechanisms,"(1) in Clinical Cancer Research, a journal published by the American Association for Cancer Research. The study details the development of the Personalis Neoantigen Presentation Score (NEOPS™), a novel composite biomarker for predicting response to cancer immunotherapy. Enabled by comprehensive tumor immunogenomic profiling from the Personalis NeXT Platform, NEOPS simultaneously models both neoantigen burden and immune-related resistance mechanisms to better predict immunotherapy response in a cohort of late-stage melanoma patients. In this study, NEOPS was more strongly predictive of therapy response than other standard single analyte and investigational biomarkers tested, including tumor mutational b
The Consortium Welcomes Playtech’s Confirmed Recommendation for Its Binding Agreement to Acquire Finalto and Urges Investors to Vote in Favour at the Playtech Adjourned General Meeting on 18 August 20212.8.2021 19:41:00 CEST | Press release
Finalto S.P.V. Ltd, the consortium led by Barinboim Group and backed by Leumi Partners Limited and Menora Mivtachim Group, together with key members of the Finalto Business' management team (together the "Consortium"), welcomes the announcement by Playtech plc (“Playtech”) confirming its recommendation that shareholders vote in favour of the Consortium’s binding agreement for Finalto Group (“Finalto) (the “Binding Agreement”). Playtech announced today that following its engagement with Gopher Investments (“Gopher”) over the past three weeks, it has not received responses from Gopher to a number of its questions and therefore “Playtech has not yet been able to achieve the necessary clarity on Gopher's ultimate ownership and funding structure, source of funds or ability to obtain the required regulatory clearances”. Shareholders should ask why Gopher continues to hide and should also be suspicious of Gopher’s credibility, particularly given that disclosure is crucial when buying a highly
Lenovo Climbs 65 Places to Record #159 On ‘FORTUNE Global 500’ List2.8.2021 17:09:00 CEST | Press release
After achieving historical 2021 fiscal year results, Lenovo has been ranked #159 on FORTUNE’s annual Global 500 List and in the top 20 (#15) of all Technology sector companies cited in the List. Lenovo jumped 65 spots this year to an all-time high ranking due to its record financial results, which saw the Group surge past the US$60 billion revenue mark, and adding more than US$10 billion from the previous fiscal year as all core businesses grew. The Fortune Global 500 is the annual ranking of the largest 500 corporations in the world as measured by total revenue. Together, companies on The Global 500 generated US$31.7 trillion in revenue and US$1.6 trillion in profits in 2020, employ 69.7 million people worldwide and are represented by 31 countries. Lenovo’s updated ranking reflects the company’s clear strategy, product innovation, operational excellence, and global/local footprint within the past year. These results reinforced the company’s resilience and ability to achieve balanced,
From Panasonic i-PRO Sensing Solutions to “i-PRO”, Renewing Its Company Name From April 20222.8.2021 17:00:00 CEST | Press release
Panasonic i-PRO Sensing Solutions Co., Ltd. will renew its company name to "i-PRO Co., Ltd." on April 1, 2022. Our company was established in October 2019 as a business separation from Panasonic Corporation, and we have incorporated the network camera brand "i-PRO" into our company name. With the new brand "i-PRO", we have been developing and delivering products that incorporate various innovations to our customers, with "Extend human senses through technology, to capture moments of truth so the front-line professionals can act." as our brand purpose for our existence in society. With our global headquarters located in Japan, we will continue our daily efforts to innovate and develop a range of products under the global brand name "i-PRO", which will be launched in markets around the world. In advance of it, i-PRO EMEA B.V. will be headquartered in Amsterdam and start operations as of October 1st, 2021, in the transition of its European Security and Industrial Medical Vision (IMV) busi
Technology Innovation Institute Appoints Eminent Technologist Dr Ray O. Johnson as CEO2.8.2021 15:54:00 CEST | Press release
Technology Innovation Institute (TII), the applied research pillar of the Advanced Technology Research Council (ATRC), the overarching advanced technology body in Abu Dhabi responsible for driving research and development for transformative technology outcomes, today announced the appointment of veteran technologist and entrepreneur Dr Ray O. Johnson as Chief Executive Officer. Dr Johnson will work on shaping the strategic direction of the Institute and lead the execution of its growth strategies to achieve operational excellence. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20210802005462/en/ Dr Ray O. Johnson, Chief Executive Officer, Technology Innovation Institute (Photo: AETOSWire) Prior to joining TII, Dr Johnson was an Operating Partner at Bessemer Venture Partners, a top-tier American venture capital company that has been part of 130 IPOs in the last 50 years, and before that, he was the Corporate Senior Vice Preside
In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.Visit our pressroom